The controlled-substance and addiction-care markets face a multibillion-dollar crisis in diversion, non-adherence, and documentation gaps. iPill™ directly targets this unmet need with a patented, secure digital health platform with the potential to eliminate diversion, prove compliance, and improve patient outcomes at scale*
The Problem We Address. The High Rate and Cost of Relapse*
125,000+
Deaths Annually
Directly attributable to patients not taking their prescriptions correctly.**
90%
Relapse Rate in Year 1
Patients with opioid use disorder relapse within the first year of treatment.
3 Patented Components. Working Seamlessly Together*
Secure Dispenser
Biometrically locked, tamper-resistant device prevents misuse, diversion, and theft of controlled medications.
Patient Mobile App
Provides secure scheduling, push notifications, and video verification of the patient taking their dose.
Physician Portal
Cloud-based dashboard delivering verified, actionable usage data and automated compliance reports.
The iPill Proactive Care Platform. Predictable ROI*
iPill™ offers payers and providers the key to driving significant cost savings and improved patient outcomes. It’s a predictable business model with recurring revenue and high gross margins for iPill™.
Industry Experience. The iPill™ Leadership Team.
A seasoned team of medical, biotech, legal, technology, and healthcare operations leaders with decades of experience developing FDA-regulated devices, scaling tech companies, guiding regulatory pathways, and driving growth across behavioral health and addiction care.
John Hsu, Founder & CEO
Board-certified anesthesiologist, pain management expert, and healthcare innovator with 25+ years’ experience. Pioneered multiple FDA-regulated medical devices and holds patents advancing secure drug delivery.
Will Pedranti, Chief Operating Officer
Biotech entrepreneur, attorney, and executive with 20+ years’ experience leading FDA-regulated companies from startup to acquisition. Co-founded and led life science ventures, guiding them through regulatory pathways.
Kevin Deane, Development
Accomplished executive with expertise in developing drug delivery and medical device solutions through the full healthcare information management ecosystem.
Strategic Guidance. The iPill™ Board of Advisors.
A distinguished board of advisors composed of former federal leaders, FDA executives, venture investors, and nationally recognized experts in pain medicine, public policy, and law enforcement—each bringing deep real-world experience guiding healthcare, biotech, and public-safety innovation.
Arthur Becker, Executive Chairman
A technology investor, Arthur has successfully built multiple tech companies. He serves as Board Chair and CEO of technology and life science firms, guiding capital raises and scaling to market.
Brian Harvey, MD, PhD
Brian Harvey, MD, PhD, is a former FDA Division Director and pharmaceutical executive with extensive experience in drug development and regulatory strategy. A Yale University alumnus, he brings deep scientific and industry insight to the iPill™ Board of Directors.
Lynn Webster, MD
Lynn Webster, MD, is a nationally recognized pain management expert and Senior Fellow at the Center for U.S. Policy. A past President of the American Academy of Pain Medicine, he serves as an advisor to iPill™, guiding healthcare strategy and innovation.
Michele Leonhart
Michele Leonhart is a former DEA Administrator and career law enforcement officer who led the agency from 2010 to 2015. A trailblazer in federal service, she became the DEA’s first female Special Agent in Charge and now serves on the iPill™ Board of Directors and as Chair of the D.A.R.E. Board.
Tobias Fischli
Tobias Fischli, CFA, is the Founder and President of TAF Capital Advisors, managing portfolios for ultra–high-net-worth clients and institutions. He brings over two decades of strategic investment experience to the iPill™ Board of Directors.
Robert Saunders
Bob Saunders is a General Partner at OCA Ventures, where he leads the firm’s healthcare investment strategy. He brings over two decades of dedicated venture capital and healthcare industry leadership to the iPill™ Board of Directors.
Kathleen O'Toole PhD
Kathleen O’Toole is the former Chief of the Seattle Police Department and former Commissioner of the Boston Police Department. She brings over three decades of transformative leadership and public safety expertise to the iPill™ Security Advisory Board.
John Akre
AI Systems Advisor
An AI-systems architect and growth executive with 20+ years across Google, YouTube, Facebook, Netflix, and The Trade Desk, now founder and CEO of ad-tech venture Afford-X. He advises iPill on the AI/ML architecture and software workflows behind its secure dispensing platform.
James Gray
AI Strategy Advisor
A CIO, CPO, and data-and-AI leader with 30+ years across global enterprises and startups, including a decade at Microsoft. Founder of JamesGray.AI and a UC Berkeley executive-education instructor, he guides growth-stage companies on enterprise AI strategy and adoption.
Learn More. Contact Us.
eMail: investors@ipill.tech
Even Better: Schedule a Meeting
Disclaimers and Forward-Looking Statements
*This presentation has been prepared by iPill™ (the “Company”) solely for informational purposes. This presentation does not constitute an offer or invitation to sell or purchase securities. The information contained herein is preliminary and should not be relied upon for any purpose. The Company makes no representation or warranty, express or implied, regarding the accuracy or completeness of the information in this presentation, and shall not be liable for any such information. You should conduct your own investigation and analysis of the Company, its business, prospects, results of operations, and financial condition. Except for internal use, this information may not be excerpted, summarized, distributed, reproduced, or used without the prior written consent of the Company.
Certain statements in this presentation that are not historical facts constitute “forward-looking statements.” Forward-looking statements reflect the Company’s current strategies, plans, views, and expectations and are generally identified by words such as “believe,” “intend,” “target,” “expect,” “estimate,” “may,” “should,” “plan,” “project,” “anticipate,” “predict,” or similar expressions. These statements are not guarantees of future performance and involve numerous known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should not rely on these forward-looking statements for any purpose. All forward-looking statements herein are qualified in their entirety by this cautionary statement. The forward-looking statements in this presentation are made as of the date hereof unless otherwise stated. Neither the delivery of this presentation nor any sale of securities by the Company after the date hereof shall be construed as implying that the information remains correct or that the Company’s affairs have not changed since that date.
The Company has a limited operating history and limited personnel. Its ability to achieve its business objectives will depend on several factors, including its ability to secure significant financing to fund its current and future needs. Actual results will differ from projections, and such differences may be material.
Any investment in the Company would be speculative and involves a high degree of risk. No public market exists for the Company’s securities, and they are therefore illiquid; if you invest in the Company, you should be prepared to bear the economic risk of the investment for an indefinite period. The Company has not registered, and does not intend to register, any of its securities with the United States Securities and Exchange Commission (“SEC”) or with any state securities authorities. Neither the SEC nor any state securities regulator has passed upon the accuracy or adequacy of the information contained herein.
**The statistics referenced above reflect overall medication-related non-adherence across all therapeutic areas within the U.S. healthcare system. They are not specific to addiction treatment medications and represent general nationwide data on preventable costs and adverse outcomes associated with patients not taking prescriptions as directed.